SESSION TITLE: Bronchoscopy and Interventional Procedures Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Our objective is to analyze the diagnostic performance of transbronchial needle aspiration guided by endobronchial ultrasound(EBUS-TBNA) in diagnosing hilar/mediastinal lymphadenopathies and/or lung masses in our department and the possible effects of the learning curve.To evaluate the tolerance of the procedure by both the patient and the doctor and its complications.
METHODS: Retrospective study of all patients referred to our department(January2010-October2011)to perform EBUS-TBNA.At the end of the technique, both the patients and bronchoscopist answered a tolerance questionnaire(scale of 0 to7).
RESULTS: n=129 patients. 325 aspirations were performed.The most common indication was suspicion of malignancy( 48.8%).The most frequent final diagnosis was normal lymph nodes(46.5%),followed by neoplasm(35.6%).The sensitivity(S)and negative predictive value(NPV)for the final diagnosis of malignancy was 93,4% and 95.5%,respectively.In order to analyze learning curve effects,we study the first 25 cases and the remainder,separately,with the S and NPV of 83.3% and 94.1%,respectively,without statistically significant differences.In 63.56%,the tolerance of the technique was 5.18 ± 2.12vs4.62 ± 2.41(patient vs.bronchoscopist).With regard to complications,90.7% did not register any complication
CONCLUSIONS: EBUS-TBNA is a diagnostic tool with a high profitability in the study of hilar/mediastinal lymphadenopaties which was higher in neoplastic lymphadenopathy.In our case,there were no statistically significant differences regarding the diagnostic performance of the technique during the learning curve. EBUS-TBNA is a safe and well-tolerated method by both the patient and the endoscopist.
CLINICAL IMPLICATIONS: EBUS-TBNA is a diagnostic tool with a high profitability in the study of hilar/mediastinal lymphadenopaties
DISCLOSURE: The following authors have nothing to disclose: Estefania Luque, Maria Pavón, Ana Gómez-Bastero, Virginia Almadana, Agustin Valido, Teodoro Montemayor
No Product/Research Disclosure Information